SG11201604911VA - Novel msln targeting dna vaccine for cancer immunotherapy - Google Patents
Novel msln targeting dna vaccine for cancer immunotherapyInfo
- Publication number
- SG11201604911VA SG11201604911VA SG11201604911VA SG11201604911VA SG11201604911VA SG 11201604911V A SG11201604911V A SG 11201604911VA SG 11201604911V A SG11201604911V A SG 11201604911VA SG 11201604911V A SG11201604911V A SG 11201604911VA SG 11201604911V A SG11201604911V A SG 11201604911VA
- Authority
- SG
- Singapore
- Prior art keywords
- novel
- dna vaccine
- cancer immunotherapy
- targeting dna
- msln targeting
- Prior art date
Links
- 101150064776 Msln gene Proteins 0.000 title 1
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005896 | 2013-12-18 | ||
| PCT/EP2014/003403 WO2015090584A1 (en) | 2013-12-18 | 2014-12-17 | Novel msln targeting dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604911VA true SG11201604911VA (en) | 2016-07-28 |
Family
ID=49876343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604911VA SG11201604911VA (en) | 2013-12-18 | 2014-12-17 | Novel msln targeting dna vaccine for cancer immunotherapy |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20160317634A1 (ja) |
| EP (1) | EP3082850B1 (ja) |
| JP (1) | JP6662787B2 (ja) |
| KR (1) | KR20160130979A (ja) |
| CN (1) | CN106061500A (ja) |
| AU (1) | AU2014365900B2 (ja) |
| BR (1) | BR112016014405A2 (ja) |
| CA (1) | CA2932388A1 (ja) |
| DK (1) | DK3082850T3 (ja) |
| ES (1) | ES2747772T3 (ja) |
| HU (1) | HUE045567T2 (ja) |
| IL (1) | IL246170B (ja) |
| LT (1) | LT3082850T (ja) |
| MX (1) | MX2016007939A (ja) |
| PL (1) | PL3082850T3 (ja) |
| RU (1) | RU2016129044A (ja) |
| SG (1) | SG11201604911VA (ja) |
| SI (1) | SI3082850T1 (ja) |
| WO (1) | WO2015090584A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1951281B1 (en) | 2005-10-17 | 2015-04-15 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| US20150104413A1 (en) | 2012-01-13 | 2015-04-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| HUE052541T2 (hu) | 2013-01-15 | 2021-05-28 | Memorial Sloan Kettering Cancer Center | Immunogén WT-1 peptidek és eljárások azok alkalmazására |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| PL2988762T3 (pl) | 2013-04-25 | 2019-01-31 | Vaximm Ag | Wektory na bazie Salmonella do immunoterapii przeciwnowotworowej ukierunkowanej na gen guza Wilmsa WT1 |
| DK3082850T3 (da) | 2013-12-18 | 2019-10-07 | Vaximm Gmbh | Msln-targeteret dna-vaccine til cancerimmunterapi |
| US10905752B2 (en) * | 2015-06-18 | 2021-02-02 | Vaximm Ag | VEGFR-2 targeting DNA vaccine for combination therapy |
| EP3484503A1 (en) * | 2016-07-13 | 2019-05-22 | Vaximm AG | Process for the production of a dna vaccine for cancer immunotherapy |
| RU2019112977A (ru) * | 2016-11-04 | 2020-12-04 | Факсимм Аг | Днк-вакцина, нацеленная на wt1, для комбинированной терапии |
| SG11201907391SA (en) * | 2017-02-17 | 2019-09-27 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| RU2019132253A (ru) * | 2017-03-17 | 2021-04-19 | Факсимм Аг | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака |
| JP7352547B2 (ja) * | 2017-12-13 | 2023-09-28 | イノビオ ファーマシューティカルズ，インコーポレイティド | メソセリンを標的とするがんワクチンおよびその使用 |
| CN112638408A (zh) * | 2018-09-05 | 2021-04-09 | 万科斯蒙股份有限公司 | 用于联合疗法的靶向新抗原的dna疫苗 |
| CA3162994A1 (en) | 2020-01-13 | 2021-07-22 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
| EP1575500A4 (en) * | 2002-07-12 | 2007-01-03 | Univ Johns Hopkins | MESOTHELIN VACCINE AND MODEL SYSTEMS |
| US9200036B2 (en) * | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| CN1859851A (zh) * | 2002-07-12 | 2006-11-08 | 约翰斯霍普金斯大学 | 间皮素疫苗与模型系统 |
| WO2006137836A2 (en) | 2004-08-17 | 2006-12-28 | Research Development Foundation | Bacterial vector systems |
| RU2007137122A (ru) | 2005-03-09 | 2009-04-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем (Us) | НОВЫЙ ПРОМОТОР hTMC И ВЕКТОРЫ ДЛЯ ОПУХОЛЕСЕЛЕКТИВНОЙ И ВЫСОКОЭФФЕКТИВНОЙ ЭКСПРЕССИИ ТЕРАПЕВТИЧЕСКИХ ПРОТИВОРАКОВЫХ ГЕНОВ |
| US7935804B2 (en) * | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| LT2794849T (lt) * | 2011-12-22 | 2017-12-11 | Vaximm Ag | Didelio produktyvumo susilpnintų salmonella padermių gamybos būdas |
| CN104812890A (zh) | 2012-09-17 | 2015-07-29 | 美国健康及人类服务部 | 基于染色体重组工程的多功能口服疫苗 |
| PL2988762T3 (pl) | 2013-04-25 | 2019-01-31 | Vaximm Ag | Wektory na bazie Salmonella do immunoterapii przeciwnowotworowej ukierunkowanej na gen guza Wilmsa WT1 |
| DK3082850T3 (da) | 2013-12-18 | 2019-10-07 | Vaximm Gmbh | Msln-targeteret dna-vaccine til cancerimmunterapi |
-
2014
- 2014-12-17 DK DK14821508.0T patent/DK3082850T3/da active
- 2014-12-17 LT LT14821508T patent/LT3082850T/lt unknown
- 2014-12-17 WO PCT/EP2014/003403 patent/WO2015090584A1/en active Application Filing
- 2014-12-17 SG SG11201604911VA patent/SG11201604911VA/en unknown
- 2014-12-17 MX MX2016007939A patent/MX2016007939A/es unknown
- 2014-12-17 EP EP14821508.0A patent/EP3082850B1/en active Active
- 2014-12-17 KR KR1020167019211A patent/KR20160130979A/ko not_active Application Discontinuation
- 2014-12-17 RU RU2016129044A patent/RU2016129044A/ru unknown
- 2014-12-17 BR BR112016014405-8A patent/BR112016014405A2/pt not_active Application Discontinuation
- 2014-12-17 HU HUE14821508A patent/HUE045567T2/hu unknown
- 2014-12-17 US US15/105,739 patent/US20160317634A1/en not_active Abandoned
- 2014-12-17 CN CN201480069996.XA patent/CN106061500A/zh active Pending
- 2014-12-17 SI SI201431356T patent/SI3082850T1/sl unknown
- 2014-12-17 PL PL14821508T patent/PL3082850T3/pl unknown
- 2014-12-17 AU AU2014365900A patent/AU2014365900B2/en not_active Ceased
- 2014-12-17 ES ES14821508T patent/ES2747772T3/es active Active
- 2014-12-17 JP JP2016559513A patent/JP6662787B2/ja active Active
- 2014-12-17 CA CA2932388A patent/CA2932388A1/en not_active Abandoned
-
2016
- 2016-06-13 IL IL246170A patent/IL246170B/en not_active IP Right Cessation
-
2017
- 2017-10-17 US US15/785,743 patent/US10441645B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106061500A (zh) | 2016-10-26 |
| PL3082850T3 (pl) | 2020-01-31 |
| SI3082850T1 (sl) | 2020-01-31 |
| US10441645B2 (en) | 2019-10-15 |
| JP2017502692A (ja) | 2017-01-26 |
| CA2932388A1 (en) | 2015-06-25 |
| BR112016014405A2 (pt) | 2018-02-20 |
| IL246170B (en) | 2019-06-30 |
| KR20160130979A (ko) | 2016-11-15 |
| WO2015090584A1 (en) | 2015-06-25 |
| RU2016129044A (ru) | 2018-01-23 |
| AU2014365900B2 (en) | 2020-04-09 |
| MX2016007939A (es) | 2016-10-28 |
| HUE045567T2 (hu) | 2020-01-28 |
| IL246170A0 (en) | 2016-07-31 |
| EP3082850A1 (en) | 2016-10-26 |
| EP3082850B1 (en) | 2019-08-28 |
| US20160317634A1 (en) | 2016-11-03 |
| AU2014365900A1 (en) | 2016-07-14 |
| LT3082850T (lt) | 2019-11-11 |
| JP6662787B2 (ja) | 2020-03-11 |
| DK3082850T3 (da) | 2019-10-07 |
| ES2747772T3 (es) | 2020-03-11 |
| US20180064794A1 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246170B (en) | A new msln-targeted DNA vaccine for cancer immunotherapy | |
| HK1207967A1 (en) | Vaccine | |
| HK1202060A1 (en) | Rna formulation for immunotherapy rna | |
| SG11201500396TA (en) | Tumor vaccination | |
| EP2876161A4 (en) | VACCINE | |
| GB201223386D0 (en) | Vaccine | |
| HK1207152A1 (en) | Multivalent breast cancer vaccine | |
| ZA201500656B (en) | Marker vaccine | |
| IL241109A0 (en) | Targeted vaccines for veterinary use | |
| HK1201176A1 (en) | Antigen presenting cancer vaccine | |
| EP2925332A4 (en) | PLACENTAL IMP THERAPY AGAINST CANCER | |
| HK1202070A1 (en) | Vaccine for tumor immunotherapy | |
| HK1203817A1 (en) | Autologous cancer cell vaccine | |
| IL268677A (en) | A novel DNA-targeting PD-L1 vaccine for cancer immunotherapy | |
| SI2830593T1 (sl) | RNA formulacija za imunoterapijo | |
| GB201202090D0 (en) | Vaccine | |
| GB201107549D0 (en) | Cancer vaccine | |
| GB201217321D0 (en) | Vaccine | |
| GB201210226D0 (en) | Vaccine | |
| GB201206169D0 (en) | Vaccine | |
| GB201205599D0 (en) | Vaccine |